When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...
GlobalData on MSN1d
FDA approves Vertex’s acute pain treatment JournavxThe US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Mycobacterium abscessus is a type of nontuberculous mycobacterium that poses a significant health risk, particularly for individuals with cystic fibrosis ... the mechanisms of infection, the ...
The results were particularly promising for Staphylococcus aureus (golden staph), a major cause of drug-resistant skin and ...
The Brighterside of News on MSN15d
Breakthrough new treatment developed for retinitis pigmentosaInherited eye disorders such as retinitis pigmentosa (RP) leave millions grappling with progressive vision loss. At the heart ...
In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.
CONCLUSIONS These data support previous findings that deficiency of α 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback